

Reference:	FOI.10202.22
Subject:	Shared Care Protocols
Date of Request:	2 November 2022

Requested:

Please could I have access to any information or guidance you have around Shared Care agreements or protocols? Any information in this area would be greatly appreciated.

Clarification

The specific service area I would like information on is NHS care given to people diagnosed with ADHD. The treatment usually includes Shared Care between the GP and the specialist that has diagnosed the ADHD.

I would like to know what the guidelines given to GPs are on how to handle shared care agreements. This includes guidance for shared care between a NHS specialist and a NHS GP, but also a private Specialist and a NHS GP. I would like to also know what the guidance around prescribing Elvanse is.

Response:

Shared Care Protocols (SCP) in Hywel Dda University Health Board (UHB) are developed in conjunction with the Medicines Management Team (MMT) and local medical teams from both acute and primary care.

The decision on whether to adopt a SCP is at the discretion of the GP. This would be based on clinical aspects such as the complexity of the regime, familiarity with the drugs and conditions and importantly the robustness/evidence of a support mechanism both for the patient and the prescriber of access to specialist advice at short notice. Similarly, there is no obligation for a GP to accept a SCP from a private provider and the UHB cannot influence this as it is a clinical decision made by the prescriber.

Presently, the UHB's MMT provides guidance on prescribing to GPs, although GPs, as indicated above, will use their professional clinical judgement on whether to prescribe medications.

The UHB does not currently have a Shared Care Agreement in place for ADHD; however, one is in development.

The current prescribing criteria for Elvanse is taken from the UHB's formulary as:

“The Advisory Council on the Misuse of Drugs has recommended additional controls on lisdexamfetamine because of reports of addiction (it is not yet known what these controls will be as it is already a full CD), prescribers need to be alert for signs of abuse, addiction or diversion.”

May be transferred to Primary care once patient is stable. The HDUHB Adult ADHD service is under development.

Lisdexamfetamine dimesylate (Elvanse Adult®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.”

